Verve Therapeutics

About Verve Therapeutics

Verve Therapeutics (NASDAQ:VERV) is a biotechnology company focused on revolutionizing the treatment of cardiovascular diseases through gene editing. With a robust pipeline of innovative gene-editing therapies, Verve's main objective is to develop treatments that can permanently reduce the risk of coronary heart disease, the world's leading cause of death, with a single dose. The company leverages precise gene editing technologies, like CRISPR, to target the underlying genetic causes of these diseases, aiming to provide enduring therapeutic solutions. By focusing on the most common genetic contributors to cardiovascular risk, Verve aspires to transform the approach to heart disease prevention, moving from chronic management to one-time, potentially curative treatments.

What is Verve Therapeutics known for?

Snapshot

2018

Year founded

269

Employees

Massachusetts, United States

Head office

Loading Map...

Operations

All Locations

United States

Products and/or services of Verve Therapeutics

VERVE-101, designed to permanently turn off the PCSK9 gene in the liver for lowering LDL cholesterol and treating atherosclerotic cardiovascular disease.
VERVE-201, targeting ANGPTL3 gene for patients with heterozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease, aiming to reduce plasma lipids.
Preclinical stage programs focusing on additional genes implicated in cardiovascular disease, expanding the potential treatment options.
Gene editing technology platform, utilizing base editing to precisely target and edit specific genetic locations, potentially lowering the risk of off-target effects.
Proprietary lipid nanoparticle delivery system, developed to efficiently deliver gene editing tools to the liver, enhancing the precision and effectiveness of treatments.